DE2332663C2 - Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie - Google Patents
Verwendung von Kortikoid-Wirkstoffen zur InhalationstherapieInfo
- Publication number
- DE2332663C2 DE2332663C2 DE2332663A DE2332663A DE2332663C2 DE 2332663 C2 DE2332663 C2 DE 2332663C2 DE 2332663 A DE2332663 A DE 2332663A DE 2332663 A DE2332663 A DE 2332663A DE 2332663 C2 DE2332663 C2 DE 2332663C2
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- pregnadiene
- dioxo
- acid
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003246 corticosteroid Substances 0.000 title claims description 13
- 239000004480 active ingredient Substances 0.000 title claims description 9
- 238000002664 inhalation therapy Methods 0.000 title claims description 4
- 230000000694 effects Effects 0.000 claims description 5
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 description 37
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 14
- -1 hydroxymethylene Chemical group 0.000 description 13
- 150000004702 methyl esters Chemical class 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 101100116570 Caenorhabditis elegans cup-2 gene Proteins 0.000 description 2
- 101100116572 Drosophila melanogaster Der-1 gene Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000006192 3-phenylprop-2-enyl group Chemical group [H]\C(=C(\[H])C([H])([H])*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2332663A DE2332663C2 (de) | 1973-06-23 | 1973-06-23 | Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie |
| SE7408091A SE7408091L (en, 2012) | 1973-06-23 | 1974-06-19 | |
| ES427480A ES427480A1 (es) | 1973-06-23 | 1974-06-20 | Procedimiento para la preparacion de un agente de inhala- cion que contiene corticoides. |
| IE1292/74A IE39516B1 (en) | 1973-06-23 | 1974-06-20 | Corticoid-containing inhalant preparations |
| IL45087A IL45087A (en) | 1973-06-23 | 1974-06-21 | Inhalant preparations containing 3,20-dioxo-pregn-4-enoic acid derivatives |
| ZA00744022A ZA744022B (en) | 1973-06-23 | 1974-06-21 | Corticoid-containing inhalant preparations corticoid-containing inhalant preparations |
| BE145751A BE816709A (fr) | 1973-06-23 | 1974-06-21 | Produits pour inhalation |
| NLAANVRAGE7408421,A NL184724C (nl) | 1973-06-23 | 1974-06-21 | Werkwijze voor het bereiden van een farmaceutisch preparaat dat een corticoide bevat. |
| DD179417A DD112437A5 (en, 2012) | 1973-06-23 | 1974-06-24 | |
| JP49072169A JPS6245846B2 (en, 2012) | 1973-06-23 | 1974-06-24 | |
| DK337574A DK337574A (en, 2012) | 1973-06-23 | 1974-06-24 | |
| FR7421859A FR2233987B1 (en, 2012) | 1973-06-23 | 1974-06-24 | |
| AU70421/74A AU493830B2 (en) | 1974-06-24 | Corticoid-containing inhalant preparations | |
| GB27902/74A GB1479488A (en) | 1973-06-23 | 1974-06-24 | Corticoid-containing inhalant preparations |
| US05/714,668 US4039668A (en) | 1973-06-23 | 1976-08-16 | Corticoid-containing inhalants |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2332663A DE2332663C2 (de) | 1973-06-23 | 1973-06-23 | Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2332663A1 DE2332663A1 (de) | 1975-01-16 |
| DE2332663C2 true DE2332663C2 (de) | 1986-07-31 |
Family
ID=5885228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2332663A Expired DE2332663C2 (de) | 1973-06-23 | 1973-06-23 | Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS6245846B2 (en, 2012) |
| BE (1) | BE816709A (en, 2012) |
| DD (1) | DD112437A5 (en, 2012) |
| DE (1) | DE2332663C2 (en, 2012) |
| DK (1) | DK337574A (en, 2012) |
| ES (1) | ES427480A1 (en, 2012) |
| FR (1) | FR2233987B1 (en, 2012) |
| GB (1) | GB1479488A (en, 2012) |
| IE (1) | IE39516B1 (en, 2012) |
| IL (1) | IL45087A (en, 2012) |
| NL (1) | NL184724C (en, 2012) |
| SE (1) | SE7408091L (en, 2012) |
| ZA (1) | ZA744022B (en, 2012) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX3864E (es) * | 1975-05-27 | 1981-08-26 | Syntex Corp | Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona |
| DE2829953A1 (de) * | 1978-07-03 | 1980-01-24 | Schering Ag | Pharmazeutische zubereitung zur behandlung der kolitis ulcerosa und kolitis granulomatosa |
| US5215979A (en) * | 1985-12-19 | 1993-06-01 | Aktiebolaget Draco | 16,17-acetalsubstituted pregnane 21-oic acid derivatives |
| EP1806148A4 (en) * | 2004-10-22 | 2009-12-02 | Ono Pharmaceutical Co | THERAPEUTIC PREPARATION FOR INHALATION |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB799902A (en) * | 1954-08-11 | 1958-08-13 | Merck & Co Inc | Therapeutic preparations |
| US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
| GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| GB1381872A (en) * | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
| BE787100A (fr) * | 1971-08-06 | 1973-02-02 | Beecham Group Ltd | Composition pour le traitement de l'asthme |
| DE2150268C3 (de) * | 1971-10-04 | 1980-11-06 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Pregnansäure-Derivate, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| YU35148B (en) * | 1971-10-04 | 1980-09-25 | Schering Ag | Process for obtaining pregnane acid derivatives |
| DE2264003C2 (de) * | 1972-12-22 | 1982-11-04 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
| DE2319479C2 (de) * | 1973-04-14 | 1982-10-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
-
1973
- 1973-06-23 DE DE2332663A patent/DE2332663C2/de not_active Expired
-
1974
- 1974-06-19 SE SE7408091A patent/SE7408091L/ not_active Application Discontinuation
- 1974-06-20 IE IE1292/74A patent/IE39516B1/xx unknown
- 1974-06-20 ES ES427480A patent/ES427480A1/es not_active Expired
- 1974-06-21 ZA ZA00744022A patent/ZA744022B/xx unknown
- 1974-06-21 BE BE145751A patent/BE816709A/xx not_active IP Right Cessation
- 1974-06-21 IL IL45087A patent/IL45087A/xx unknown
- 1974-06-21 NL NLAANVRAGE7408421,A patent/NL184724C/xx not_active IP Right Cessation
- 1974-06-24 DD DD179417A patent/DD112437A5/xx unknown
- 1974-06-24 GB GB27902/74A patent/GB1479488A/en not_active Expired
- 1974-06-24 JP JP49072169A patent/JPS6245846B2/ja not_active Expired
- 1974-06-24 DK DK337574A patent/DK337574A/da unknown
- 1974-06-24 FR FR7421859A patent/FR2233987B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU7042174A (en) | 1976-01-08 |
| NL7408421A (en, 2012) | 1974-12-30 |
| DK337574A (en, 2012) | 1975-03-17 |
| SE7408091L (en, 2012) | 1974-12-23 |
| NL184724C (nl) | 1989-10-16 |
| ZA744022B (en) | 1975-06-25 |
| IL45087A (en) | 1978-04-30 |
| BE816709A (fr) | 1974-12-23 |
| JPS5047967A (en, 2012) | 1975-04-28 |
| DE2332663A1 (de) | 1975-01-16 |
| FR2233987A1 (en, 2012) | 1975-01-17 |
| FR2233987B1 (en, 2012) | 1977-07-08 |
| IE39516L (en) | 1974-12-23 |
| DD112437A5 (en, 2012) | 1975-04-12 |
| IL45087A0 (en) | 1974-09-10 |
| JPS6245846B2 (en, 2012) | 1987-09-29 |
| NL184724B (nl) | 1989-05-16 |
| GB1479488A (en) | 1977-07-13 |
| IE39516B1 (en) | 1978-10-25 |
| ES427480A1 (es) | 1976-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69521239T2 (de) | Nasal verabreichbare Mittel | |
| DE69721766T2 (de) | Neue arzneiformulierung | |
| EP4205723A1 (de) | Sulfathaltiger oder phosphataltiger, selbsthaftender dentaler kompositzement mit guter transparenz | |
| EP2723344B1 (de) | Monoterpenhaltiges kombinationstherapeutikum | |
| EP2753330A1 (de) | Therapeutische anwendungen von ectoin | |
| DE2332663C2 (de) | Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie | |
| EP0471967A1 (de) | Sucralfat-Kautablette | |
| DE2353797A1 (de) | Stabilisierung von prostaglandinen | |
| DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
| EP0100516B1 (de) | 3-Beta-(3'-(Carboxypropionyloxy))-ursa-9(11),12-dien-28-carbonsäure sowie ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2715384C3 (de) | Arzneimittel gegen Diarrhöen | |
| Obase et al. | Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study | |
| EP0509042B1 (de) | Intravenös applizierbare Pharmazeutische Zubereitung von 1-Octadecyl-2-methyl-glycero3-phosphocholin | |
| DE2243776A1 (de) | Komplexe von tetracyclinen mit tris(hydroxymethyl)-aminomethan | |
| EP0043548B1 (de) | Salz aus Furosemid oder Piretanid als Säurekomponente und Penbutolol als Basenkomponente sowie Arzneimittel, das beide Komponenten enthält | |
| DE2342460A1 (de) | Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel | |
| US4039668A (en) | Corticoid-containing inhalants | |
| EP0340540B1 (de) | Mittel zur Prophylaxe des Herzinfarkts und zur Verhütung des Reinfarkts | |
| DE2161588C3 (de) | Mittel zur Behandlung von Hyperlipoproteinämien | |
| DE2401453A1 (de) | Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen | |
| EP0461218B1 (de) | Zubereitung eines salzes von oxypurinol in oraler form zur behandlung von hyperuricämie | |
| Smith et al. | A clinical comparison of aerosol and powder administration of beclomethasone dipropionate in asthma | |
| AT408610B (de) | Zusammensetzung aus pflanzenextrakten, insbesondere zur verwendung bei der krebstherapie | |
| DE2714342C2 (de) | Bis(acetylsalicylsäure)-thiaalkandiol-ester und therapeutische Zusammensetzung | |
| DE2521765A1 (de) | Verwendung von uronsaeuren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |